Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III ALD-101 adjuvant therapy after unrelated umbilical cord blood transplantation in children with inborn errors of metabolism
NL-OMON32439Phase 3Active, not recruiting
- Sponsor
- Aldagen, Inc.
- Start
- Jun 2010
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ALD-101 in Congenital Metabolic Diseases, sponsored by Aldagen, Inc. Primary endpoints: Platelet engraftment and Neutrophil engraftment. Started Jun 2010; status: active, not recruiting.
02
Drugs
ALD-101
03
Conditions
Congenital Metabolic Diseases
Beyond the preview
Go deeper on NL-OMON32439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32439.